DELLPHI-303

NCT05361395 📎

Regimen

Experimental
tarlatamab + atezolizumab or durvalumab as maintenance after first-line chemo-immunotherapy
Control
no control (single-arm)

Population

Extensive-stage small-cell lung cancer without progression after first-line chemo-immunotherapy

Key finding

mOS 25.3 mo (95% CI 20.3-NE) from start of maintenance; CRS 24% serious; manageable safety; phase 3 NCT06211036 ongoing

Source: PMID 40934933

Timeline

    Guideline citations

    • CSCO SCLC 2025 (p.67)⚠️ OCR source